

3 April 2024

Updates to ASX announcement dated 2 April 2024 “Osteopore issues Replacement Prospectus for Entitlement Offer”

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – would like to provide an update on the ASX announcement released on 2 April 2024, in relation to the 10-for-1 Renounceable Pro-Rata Entitlement Offer at A\$0.029 per share to raise ~A\$3,000,000 (before costs) (**Entitlement Offer**).

As a result of discussions with ASX, the Company notifies that:

- the Entitlement Offer closed on 2 April 2024;
- a second replacement prospectus will be issued; and
- an application will be lodged to withdraw the replacement prospectus lodged on 2 April 2024.

The second replacement prospectus is required to provide additional information for applicants, confirm the closing date of 2 April 2024 in the original prospectus, and provide applicants with the right to withdraw their application and instructions on how to obtain a refund of application monies on request.

The changes to be made in the replacement prospectus from the original prospectus are:

- additional information relating to regulatory approvals and other expansion plans;
- amending the summary of important dates, and the timeline to reflect the adjusted timeline resulting from the replacement prospectus;
- key risk factors expanded to include risks relating to share liquidity and future capital needs and additional funding;
- including additional information regarding potential increases in substantial shareholders interests;



- amending the wording regarding eligibility for the Shortfall Offer and Entitlement Offer to clarify that the section 606 reference is intended to be a reference to a prohibition to shareholders exceeding the 19.9% threshold;
- including additional information explaining the use of funds received from the Entitlement Offer;
- including additional information relating to the Company specific risk of loss-making operation, future capital needs and additional funding;
- including ASX announcements made under the Company's continuous disclosure obligations since the date of the original prospectus; and
- providing applicants with a right to withdraw their application and instructions on how to obtain a refund of application monies on request.

The Company is reconciling the funds raised and will announce the results of the Entitlement Offer on 5 April 2024 in accordance with the timetable stated in the original prospectus dated and lodged with ASX on 13 March 2024. An updated Appendix 3B will be lodged with ASX when the Company has received approval from ASIC on the replacement prospectus.

ENDS

This announcement dated 3 April 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com**Isaac Stewart**

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au**About Osteopore Limited**

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.



Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

